Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.
Abstract
Epidermal growth factor receptor (EGFR) is a well-exploited therapeutic target in metastatic colorectal cancer (mCRC). Unfortunately, not all patients benefit from current EGFR inhibitors. Mass spectrometry–based proteomics and phosphoproteomics were performed on 30 genomically and pharmacologically characterized mCRC patient–derived xenografts (PDXs) to investigate the molecular basis of response to EGFR blockade and identify alternative drug targets to overcome resistance. Both the tyrosine and global phosphoproteome as well as the proteome harbored distinctive response signatures. We found that increased pathway activity related to mitogen-activated protein kinase (MAPK) inhibition and abundant tyrosine phosphorylation of cell junction proteins, such as CXADR and CLDN1/3, in sensitive tumors, whereas epithelial-mesenchymal transition and increased MAPK and AKT signaling were more prevalent in resistant tumors. Furthermore, the ranking of kinase activities in single samples confirmed the driver activity of ERBB2, EGFR, and MET in cetuximab-resistant tumors. This analysis also revealed high kinase activity of several members of the Src and ephrin kinase family in 2 CRC PDX models with genomically unexplained resistance. Inhibition of these hyperactive kinases, alone or in combination with cetuximab, resulted in growth inhibition of ex vivo PDX-derived organoids and in vivo PDXs. Together, these findings highlight the potential value of phosphoproteomics to improve our understanding of anti-EGFR treatment and response prediction in mCRC and bring to the forefront alternative drug targets in cetuximab-resistant tumors.
Overview
CoChat Summary
TL;DR
Mass-spectrometry proteomics and phosphoproteomics of 30 metastatic colorectal cancer patient-derived xenografts identified phosphosite and protein signatures distinguishing cetuximab-sensitive from cetuximab-resistant tumors and nominated hyperactive kinases, including EPHA2/Src family kinases, as targets in genomically unexplained resistance. Dasatinib alone or with cetuximab inhibited growth in CRC0161 organoids and blocked tumor growth in CRC0166 PDX tumors in vivo.
Key findings
- In 30 mCRC PDXs (10 cetuximab-sensitive, 20 cetuximab-resistant), the proteome contained 5287 proteins and the phosphoproteome contained 13,110 class-I phosphosites (8973 pSer, 1066 pThr, 3073 pTyr) on 15,095 phosphopeptides from 5207 phosphoproteins, including 255 kinases of which 53 were tyrosine kinases. Differential comparisons yielded 53 phosphosites and 53 proteins for CS vs CR-ALL, 75 phosphosites and 49 proteins for CS vs CR-MUT, and 17 phosphosites and 72 proteins for CS vs CR-WT (P < 0.01, fold change > 1.5).
- Sensitive tumors showed increased tyrosine phosphorylation of cell junction proteins such as CXADR and CLDN1/3, enrichment of OXPHOS, Myc targets, and adipogenesis, and enrichment of signatures related to MEK1/2 inhibitor U0126 and p38 MAPK inhibitor losmapimod. Resistant tumors showed enrichment of EMT, AKT1, and MAPK signaling; PTM-SEA found TSLP and ABL1 pathways enriched in resistant tumors (FDR P < 0.05), and CXADR RNA expression was significantly higher in CS models in both RNA400 and RNAsub comparisons (P < 0.05).
- INKA analysis confirmed driver activity of ERBB2, EGFR, and MET in cetuximab-resistant tumors with corresponding gene amplifications, and revealed high Src and ephrin kinase family activity in two CRC PDX models with genomically unexplained resistance (CRC0161 and CRC0166). Dasatinib reduced viability in CRC0161 organoids in the micro- to nanomolar range but not in control models CRC0196 and CRC0254; low-dose cetuximab (0.7 μg/ml, ~5 nM) plus dasatinib (5 nM) impaired viability whereas either alone was ineffective, and high-dose cetuximab (140 μg/ml, ~1000 nM) reduced viability by only about 40% versus about 80% for dasatinib (1000 nM).
- In vivo, CRC0166 PDX tumors treated for 3 weeks showed no control by dasatinib alone, only retarded growth with cetuximab alone, and tumor volume increased by 40% on average; the combination of dasatinib and cetuximab completely blocked tumor growth, with a significant advantage in tumor volumetric reduction compared with single-agent cetuximab (P = 0.0377).
Methods
- Label-free LC-MS/MS proteomics and phosphoproteomics were performed on 30 genomically characterized mCRC PDX tumors (10 CS, 20 CR), using pTyr immunoprecipitation, TiO2-based global phosphopeptide enrichment, and protein-expression profiling; biological and technical replicates were measured for reproducibility, and seven samples were excluded from TiO2 data due to technical failure or high variation/low peptide yield.
- Group comparisons were made for CS vs CR-ALL, CS vs CR-MUT, and CS vs CR-WT using limma for phosphosite intensities and a beta-binomial test (ibb) for protein expression, with filters of P < 0.01, fold change > 1.5, and >50% data coverage in at least one group; downstream analyses included GSEA, PTM-SEA, STRING/Cytoscape network analysis, MCL clustering, and single-sample INKA kinase activity ranking.
- Functional validation used organoids derived from PDX models CRC0161, CRC0196, and CRC0254 for CellTiter-Glo viability assays with one-way ANOVA, and in vivo PDX experiments in CRC0166 treated for 3 weeks with cetuximab (20 mg/kg intraperitoneal, twice weekly), dasatinib (50 mg/kg oral gavage, daily), or the combination, with tumor volume measured by caliper.
Limitations
- Stated: the analyses focused on static interrogation of phosphoprotein and protein biomarkers in treatment-naïve PDX tumors and correlated results with cetuximab outcome, so dynamic changes over therapy were not assessed; the association between cetuximab resistance and high EPHA2 and Src family kinase activity was not validated in clinical samples from therapeutically annotated mCRC patients; CRC0161 organoid results could not be confirmed in vivo because it failed to re-engraft as PDX, and CRC0166 could not be grown as organoids but was tested in vivo.
- Evident from the text: functional validation of the dasatinib hypothesis rests on two genomically unexplained resistant models (CRC0161 and CRC0166), limiting broader generalizability, and the clinical relevance of the nominated kinase targets remains untested in patient samples.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 39 Not checked · 108 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pTyr signature predominantly consisted of phosphosites with increased phosphorylation in sensitive tumors, whereas the global TiO 2 -based signatures contained almost only phosphosites that were more phosphorylated in resistant tumors.”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Comparing significant phosphosites [P < 0.01, fold change (FC) > 1.5] from the three group comparisons (CS versus CR-ALL, CS versus CR-MUT, and CS versus CR-WT) shows an overlap of phosphosites that either fall into a general response signature (CS1/2/3, CR1/2/3) or a signature for either Ras/Raf-mutated (CS4, CR4) or WT tumors (CS5, CR5) (Fig. 1A and table S3).”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, the global TiO 2 phosphorylation signatures additionally separated CR-MUT from CR-WT tumors.”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Table S5 shows that the spectrum identifications based on the combined search resulted in precisely the same underlying set of peptide sequences for each phosphosite.”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“75 (8 pTyr and 67 TiO 2 ) differentially phosphorylated phosphosites and 49 proteins in CS versus CR tumors with oncogenic mutations in KRAS, NRAS, or BRAF (CR-MUT);”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 147 claims and every source verdict.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 36
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Differential (phospho)proteome profiles of cetuximabsensitive and -resistant PDX tumors provide insight into molecular determinants of response to cetuximab
“a signature for either Ras/Raf-mutated (CS4, CR4) or WT tumors (CS5, CR5)”
§ Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer > Supplementary Materials
“parts without overlap (S/R4 and S/ R5) are distinctive for, respectively, CR-WT and CR-MUT.”
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1074 · Cited by 8,056
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1106 · Cited by 6,693
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Fast gene set enrichment analysis
Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M. N., & Sergushichev, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060012 · Cited by 3,454
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M., Latham, V., & Skrzypek, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1267 · Cited by 3,411
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
ggplot2: Elegant Graphics for Data Analysis (2nd ed.)
Villanueva, R. A. M., & Chen, Z. J. (2019) · Measurement: Interdisciplinary Research and Perspectives · doi:10.1080/15366367.2019.1565254 · Cited by 1,219
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 944
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Self-citationThe target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“Targets denoted by triangles were found using a chemical proteomics approach (32), and those denoted by circles were identified using cell-free assays (33, 62, 63).”
MethodArnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Self-citationSchwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
clusterMaker: a multi-algorithm clustering plugin for Cytoscape
Morris, J. H., Apeltsin, L., Newman, A. M., Baumbach, J., Wittkop, T., Su, G., Bader, G. D., & Ferrin, T. E. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-436 · Cited by 621
Loss of tight junction barrier function and its role in cancer metastasis
Martin, T. A., & Jiang, W. G. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.11.005 · Cited by 492
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 6×
“In this study, we combined mass spectrometry–based proteomics with global (TiO2) and pTyr-based phosphoproteomics to analyze a unique panel of 30 genomically characterized mCRCPDX tumors annotated for response to cetuximab as seen in the clinic and confirmed in the mouse setting (10).”
BackgroundMethodInfluentialSelf-citationPrice, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Sugiyama, N., Masuda, T., Shinoda, K., Nakamura, A., Tomita, M., & Ishihama, Y. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t600060-mcp200 · Cited by 435
A Curated Resource for Phosphosite-specific Signature Analysis
Krug, K., Mertins, P., Zhang, B., Hornbeck, P., Raju, R., Ahmad, R., Szucs, M., Mundt, F., Forestier, D., Jane-Valbuena, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir118.000943 · Cited by 338
Genenames.org: the HGNC and VGNC resources in 2017
Yates, B., Braschi, B., Gray, K. A., Seal, R. L., Tweedie, S., & Bruford, E. A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1033 · Cited by 328
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · cited 1×
“The cluster enzyme-linked receptor protein signaling included proteins involved in AKT1 signaling, where the PI3K-PTEN-AKT signaling axis is known to be involved in resistance to EGFR inhibitors (23).”
BackgroundMulvihill, M. J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., et al. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.89 · Cited by 311
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
Self-citationIsella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302
Self-citationIntegrated Omics of Metastatic Colorectal Cancer
Li, C., Sun, Y.-D., Yu, G.-Y., Cui, J.-R., Lou, Z., Zhang, H., Huang, Y., Bai, C.-G., Deng, L.-L., Liu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.002 · Cited by 297
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0499 · Cited by 280
Regulation of mitochondrial oxidative phosphorylation through cell signaling
Hüttemann, M., Lee, I., Samavati, L., Yu, H., & Doan, J. W. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.10.001 · Cited by 266
Dunne, P. D., Dasgupta, S., Blayney, J. K., McArt, D. G., Redmond, K. L., Weir, J.-A., Bradley, C. A., Sasazuki, T., Shirasawa, S., Wang, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0603 · Cited by 141
Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, M., Tian, Y., & Go, W. Y. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.009 · Cited by 128
Visualize omics data on networks with Omics Visualizer, a Cytoscape App
Legeay, M., Doncheva, N. T., Morris, J. H., & Jensen, L. J. (2020) · F1000Research · doi:10.12688/f1000research.22280.1 · Cited by 128
Galimi, F., Torti, D., Sassi, F., Isella, C., Corà, D., Gastaldi, S., Ribero, D., Muratore, A., Massucco, P., Siatis, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3377 · Cited by 124
Self-citationZanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
Self-citationLeto, S. M., Sassi, F., Catalano, I., Torri, V., Migliardi, G., Zanella, E. R., Throsby, M., Bertotti, A., & Trusolino, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3066 · Cited by 104
Self-citationINKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Beekhof, R., van Alphen, C., Henneman, A. A., Knol, J. C., Pham, T. V., Rolfs, F., Labots, M., Henneberry, E., Le Large, T. Y., de Haas, R. R., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188250 · Cited by 97
Self-citationLeech, A. O., Cruz, R. G. B., Hill, A. D. K., & Hopkins, A. M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.01 · Cited by 87
Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
Self-citationDrug Sensitivity Assays of Human Cancer Organoid Cultures
Francies, H. E., Barthorpe, A., McLaren-Douglas, A., Barendt, W. J., & Garnett, M. J. (2016) · Methods in Molecular Biology · doi:10.1007/7651_2016_10 · Cited by 81
An accurate paired sample test for count data
Pham, T. V., & Jimenez, C. R. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts394 · Cited by 72
Self-citationRivera, M., Fichtner, I., Wulf-Goldenberg, A., Sers, C., Merk, J., Patone, G., Merve, K., Kanashova, T., Mertins, P., Hoffmann, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.11.005 · Cited by 72
Piersma, S. R., Knol, J. C., de Reus, I., Labots, M., Sampadi, B. K., Pham, T. V., Ishihama, Y., Verheul, H. M. W., & Jiménez, C. R. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.03.019 · Cited by 57
Self-citationEvaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
van der Mijn, J. C., Labots, M., Piersma, S. R., Pham, T. V., Knol, J. C., Broxterman, H. J., Verheul, H. M. W., & Jiménez, C. R. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.04.006 · Cited by 57
Self-citationChemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs
Heinzlmeir, S., Kudlinzki, D., Sreeramulu, S., Klaeger, S., Gande, S. L., Linhard, V., Wilhelm, M., Qiao, H., Helm, D., Ruprecht, B., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00709 · Cited by 56
Koch, H., Busto, M. E. D. C., Kramer, K., Médard, G., & Küster, B. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00161 · Cited by 54
Jiménez, C. R., & Verheul, H. M. W. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e504 · Cited by 52
Self-citationKIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation
Pike, R., Zapater, E. O., Lumicisi, B., Santis, G., & Parsons, M. (2018) · Science Signaling · doi:10.1126/scisignal.aaq1060 · Cited by 46
Solmi, R., Lauriola, M., Francesconi, M., Martini, D., Voltattorni, M., Ceccarelli, C., Ugolini, G., Rosati, G., Zanotti, S., Montroni, I., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-227 · Cited by 41
Impact of phosphoproteomics in the translation of kinase‐targeted therapies
Casado, P., Hijazi, M., Britton, D., & Cutillas, P. R. (2016) · PROTEOMICS · doi:10.1002/pmic.201600235 · Cited by 36
Labots, M., van der Mijn, J. C., Beekhof, R., Piersma, S. R., Haas, R. R. D. G., Pham, T. V., Knol, J. C., Dekker, H., van Grieken, N. C. T., Verheul, H. M. W., et al. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.04.014 · Cited by 35
Self-citationKIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
Liu, Y., Yang, H., Cao, J., Jiang, Y., Hao, J., Xu, X., Cai, Y., & Wang, M. (2016) · Scientific Reports · doi:10.1038/srep24786 · Cited by 33
Helden, E. J. V., van Oordt, C. W. M. D. H., Heymans, M. W., Ket, J. C. F., van den Oord, R., & Verheul, H. M. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9668-y · Cited by 28
Self-citationStrimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.07.001 · Cited by 27
Labots, M., Pham, T. V., Honeywell, R. J., Knol, J. C., Beekhof, R., Haas, R. D. G.-D., Dekker, H., Neerincx, M., Piersma, S. R., van der Mijn, J. C., et al. (2020) · Cancers · doi:10.3390/cancers12020330 · Cited by 22
Self-citationRolfs, F., Piersma, S. R., Dias, M. P., Jonkers, J., & Jiménez, C. R. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100078 · Cited by 19
Self-citation
Cited by
Mao, Y., Shangguan, D., Huang, Q., Xiao, L., Cao, D., Zhou, H., & Wang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02321-x · Cited by 114
Kiran, N. S., Yashaswini, C., Maheshwari, R., Bhattacharya, S., & Prajapati, B. G. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00008 · Cited by 80
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 71
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Li, J., Gu, A., Tang, N., Zengin, G., Li, M., & Liu, Y. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250016 · Cited by 69
Crosstalk between metabolic and epigenetic modifications during cell carcinogenesis
Gao, Y., Zhang, S., Zhang, X., Du, Y., Ni, T., & Hao, S. (2024) · iScience · doi:10.1016/j.isci.2024.111359 · Cited by 47
Metadata
- Authors
- Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., Henneman, A. A., Knol, J. C., Pham, T. V., de Goeij-de Haas, R., Piersma, S. R., Labots, M., Verheul, H. M. W., Trusolino, L., & Jimenez, C. R.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Candiolo Cancer Institute (IT)
- The Netherlands Cancer Institute (NL)
- Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
- Erasmus MC (NL)
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2023-08-16
- Volume
- 15
- Issue
- 709
- Pages
- eabm3687-eabm3687
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4385857908
- Semantic Scholar
- f43ca73cc8a902fa7f7c940d4750ed56670991bc
- Cited by
- 39
- References
- 62
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- Science Translational Medicine (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Cancer Research UK (22795)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91116017, 22802)
- Associazione Italiana per la Ricerca sul Cancro (AIRC5x1000, 22802, 21091, 20697, 22795)
- Cancer Center Amsterdam
- Horizon 2020 Framework Programme (731105 EDIReX, 754923, 731105)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR inhibition, cetuximab resistance, metastatic colorectal cancer, patient-derived xenografts, phosphoproteomics, tyrosine phosphorylation, MAPK signaling, Akt signaling, epithelial-mesenchymal transition, ERBB2, MET, Src family kinases, cell junction proteins, organoids, drug resistance markers, combination therapy
- MeSH terms
- Cetuximab, Antineoplastic Agents, Colonic Neoplasms, Humans, Phosphoproteins, Phosphorylation, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Proteome, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.